These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637 [Abstract] [Full Text] [Related]
3. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Halfon P, Pérusat S, Bourlière M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chêne G, Couzigou P, ANRS HC16 GAMMATRI Study Group. J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789 [Abstract] [Full Text] [Related]
4. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H. J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591 [Abstract] [Full Text] [Related]
5. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C. Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators. Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072 [Abstract] [Full Text] [Related]
7. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D. Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395 [Abstract] [Full Text] [Related]
18. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice. Niederau C, Mauss S, Böker K, Lutz T, Heyne R, Moog G, John C, Witthöft T, Alshuth U, Hüppe D. Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351 [Abstract] [Full Text] [Related]